Efficacy and toxicity of addition of bevacizumab to chemotherapy in patients with metastatic colorectal cancer.

CONCLUSION: Our results suggest that the addition of bevacizumab to the chemotherapy therapy could be an efficient and safe treatment option for patients with metastatic colorectal cancer as second-line therapy and without increase the risk of adverse event.
PMID: 30663563 [PubMed - as supplied by publisher]

Source: Combinatorial Chemistry and High Throughput Screening - January 19, 2019 Category: Chemistry Authors: Ruan WC, Che YP, Ding L, Li HF Tags: Comb Chem High Throughput Screen Source Type: research